4,5-Dimethylpyridin-3-amine | 1335056-01-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4,5-Dimethylpyridin-3-amine
• CAS: 1335056-01-3
• 化学式: C₇H₁₀N₂
• 分子量: 122.17
• InChiKey: YFBUVAGRKDHZCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS INHIBITORS OF HPK1<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE HPK1
  申请人：GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD

  公开号：WO2021004547A1

  公开（公告）日：2021-01-14

  This disclosure relates to heterocyclics as inhibitors of HPK1, in particular relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising said compound that useful for treatment of HPK1 mediated diseases and conditions such as cancer. (I)

  这项披露涉及杂环化合物作为HPK1的抑制剂，特别涉及公式I的化合物或其药用盐，以及包含该化合物的药物组合物，用于治疗HPK1介导的疾病和状况，如癌症。 (I)
• INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA
  申请人：D'ORCHYMONT Hugues

  公开号：US20070185187A1

  公开（公告）日：2007-08-09

  The invention relates to methods of treating or preventing malaria which comprises administering to a patient in need thereof, an effective amount of a 1H-indazole-3-carboxamide derivative of general formula (I), in the form of a base or of an addition salt with an acid, or in the form of a hydrate or of a solvate of said base or acid addition salt.

  该发明涉及治疗或预防疟疾的方法，包括向需要的患者施用一种通式（I）的1H-吲唑-3-羧酰胺衍生物的有效量，其为碱式或与酸形成的加合盐的形式，或为所述碱式或酸性加合盐的水合物或溶剂化合物的形式。
• [EN] METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS<br/>[FR] PROCÉDÉS D'UTILISATION D'INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT/β-CATÉNINE
  申请人：SAMUMED LLC

  公开号：WO2018075858A1

  公开（公告）日：2018-04-26

  This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

  本公开涉及使用一种或多种吲唑-3-羧酰胺化合物或其盐或类似物，用于治疗独立选择自包括肌腱病、皮炎、牛皮癣、硬皮病、鱼鳞病、雷诺综合征和达里尔病的一种或多种疾病或症状；和/或促进伤口愈合。方法包括向受试者（例如，需要者）施用如本文中任何地方所述的一种或多种吲唑-3-羧酰胺化合物或其盐或类似物的治疗有效量。
• [EN] CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER<br/>[FR] COMPOSÉS DE CINNOLINE POUR LE TRAITEMENT DE TROUBLES DÉPENDANT DU HPK1 TELS QUE LE CANCER
  申请人：GENENTECH INC

  公开号：WO2020069402A1

  公开（公告）日：2020-04-02

  Cinnoline compounds of formula (I), variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.

  该文描述了化学式(I)的喹啉化合物及其变体，以及它们作为HPK1（造血激酶1）抑制剂的用途。这些化合物在治疗HPK1依赖性疾病和增强免疫反应方面具有用途。还描述了抑制HPK1的方法、治疗HPK1依赖性疾病的方法、增强免疫反应的方法以及制备喹啉化合物的方法。
• INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/BETA-CATENIN SIGNALING PATHWAY INHIBITORS
  申请人：Samumed, LLC

  公开号：US20140045815A1

  公开（公告）日：2014-02-13

  Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  本发明揭示了用于治疗各种疾病和病理的吲唑并[3,2-c]吡唑-3-羧酰胺化合物。更具体地，本发明涉及使用吲唑并[3,2-c]吡唑-3-羧酰胺化合物或其类似物，治疗由Wnt通路信号激活引起的疾病（例如癌症，异常细胞增殖，血管生成和骨关节炎），调节由Wnt通路信号介导的细胞事件，以及由于Wnt通路和/或Wnt信号组分之一或多个的突变或失调引起的遗传疾病和神经系统疾病/疾病/病症。还提供了治疗Wnt相关疾病状态的方法。